Telitacicept ( DrugBank: - )


2 diseases
告示番号疾患名(ページ内リンク)臨床試験数
48原発性抗リン脂質抗体症候群1
49全身性エリテマトーデス1

48. 原発性抗リン脂質抗体症候群


臨床試験数 : 4 薬物数 : 5 - (DrugBank : 3) / 標的遺伝子数 : 0 - 標的パスウェイ数 : 0
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05078710
(ClinicalTrials.gov)
July 1, 202124/9/2021Telitacicept in Primary APS PatientsA Pilot Study of Telitacicept Treatment in Primary APS PatientsAnti Phospholipid SyndromeDrug: TelitaciceptPeking Union Medical College HospitalNULLRecruiting18 Years65 YearsAll20Phase 2China

49. 全身性エリテマトーデス


臨床試験数 : 946 薬物数 : 722 - (DrugBank : 186) / 標的遺伝子数 : 117 - 標的パスウェイ数 : 199
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05247203
(ClinicalTrials.gov)
April 202226/1/2022Telitacicept Study in Chinese Subjects With Systemic Lupus ErythematosusA Phase I, Multiple-Dose Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Telitacicept in Chinese Subjects With Systemic Lupus Erythematosus (SLE)Systemic Lupus ErythematosusBiological: Telitacicept;Drug: standard therapyRemeGen Co., Ltd.NULLNot yet recruiting18 Years65 YearsAll75Phase 1China